HORIZON-PFT Trial: A Plain-English Overview of What It Established

At a glance

| Detail | Value | |---|---| | Full Title | Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly, Key Fracture Trial | | N | 7,765 postmenopausal women | | Intervention | Zoledronic acid 5 mg IV once yearly (3 infusions total) | | Comparator | Matching IV placebo | | Duration | 3 years | | Primary Endpoint | New morphometric vertebral fracture | | Key Result | 70% relative risk reduction in vertebral fractures (3.3% vs. 10.9%) | | Published | 2007, New England Journal of Medicine | | ClinicalTrials.gov | NCT00049829 |

The Question the Trial Asked

Before HORIZON-PFT, oral bisphosphonates like alendronate and risedronate were the standard treatment for postmenopausal osteoporosis. They worked, but real-world adherence was poor. Studies found that roughly half of patients stopped their oral bisphosphonate within the first year, largely because of gastrointestinal side effects and the inconvenience of fasting and staying upright after each dose.

Zoledronic acid, already approved at higher doses for cancer-related bone disease, had the pharmacologic potency to suppress bone resorption for a full year from a single infusion. The core question was simple: could one 15-minute IV drip per year match or exceed the fracture reduction seen with daily or weekly pills, while sidestepping the adherence problem entirely?

The HORIZON-PFT investigators designed the trial to answer that question with a hard clinical endpoint (actual fractures), not just bone density changes.

Who Was Enrolled

The trial recruited 7,765 postmenopausal women aged 65 to 89 from 240 centers across 27 countries. To qualify, women needed a femoral neck bone mineral density (BMD) T-score of <−1.5 with at least one existing vertebral fracture, or a T-score of <−2.5 with or without a prior fracture.

Patients already on oral bisphosphonates could enroll after a washout period. Women with recent parathyroid hormone use, active cancer, or a creatinine clearance below 30 mL/min were excluded. Approximately 79% of participants were white, with a mean age of 73 years, reflecting the population most commonly affected by osteoporotic fractures in clinical practice.

All participants received daily calcium (1,000 to 1 to 500 mg) and vitamin D (400 to 1 to 200 IU). The investigators measured 25-hydroxyvitamin D levels at baseline and required repletion in deficient patients before the first infusion, a methodological detail that later influenced FDA labeling recommendations for Reclast.

What They Were Given

Participants were randomized 1:1 to receive either zoledronic acid 5 mg or placebo, delivered as a 15-minute intravenous infusion at baseline, 12 months, and 24 months (three total infusions over the trial). Randomization was stratified by the number of baseline vertebral fractures and by prior bisphosphonate use.

The infusion protocol allowed pretreatment with acetaminophen to reduce acute-phase reactions (fever, myalgia, headache) commonly seen within the first three days after an infusion. These reactions occurred in approximately 32% of patients after the first dose but dropped to under 7% after the second and third infusions.

What Was Measured

The primary endpoint was the incidence of new morphometric vertebral fractures over three years, identified by scheduled lateral spine radiographs at 12, 24, and 36 months and read centrally by blinded experts.

Key secondary endpoints included hip fracture, any clinical fracture, clinical vertebral fracture, and changes in BMD at the lumbar spine, total hip, and femoral neck.

Morphometric vertebral fractures were defined using the Genant semiquantitative grading system, where a vertebral height reduction of 20% or more from baseline qualified as a new fracture. Central reading by two independent radiologists reduced observer bias, a design strength that many earlier bisphosphonate trials did not employ.

What the Trial Found

The results, published in the NEJM in May 2007, were unambiguous across every fracture category.

Fracture Outcomes at 3 Years

| Endpoint | Zoledronic Acid | Placebo | Relative Risk Reduction | p-value | |---|---|---|---|---| | Morphometric vertebral fracture | 3.3% | 10.9% | 70% | <0.001 | | Hip fracture | 1.4% | 2.5% | 41% | 0.002 | | Non-vertebral fracture | 8.0% | 10.7% | 25% | <0.001 | | Clinical vertebral fracture | 0.5% | 2.6% | 77% | <0.001 | | Any clinical fracture | 8.4% | 12.8% | 33% | <0.001 |

The vertebral fracture benefit was visible by 12 months and sustained through year three. BMD gains reinforced the fracture data: lumbar spine BMD increased by 6.7% and total hip by 6.0% relative to placebo over 36 months.

Bone Turnover Markers

Serum C-telopeptide (CTX), a marker of bone resorption, dropped sharply within the first week after infusion and remained suppressed throughout each dosing interval. Bone-specific alkaline phosphatase (BSAP), a formation marker, declined more gradually. Both markers tracked closely with the fracture reduction timeline, confirming sustained pharmacologic activity from a single annual dose.

Safety Profile: What the Investigators Reported

Serious adverse events occurred at similar rates in both groups (29.2% zoledronic acid vs. 30.1% placebo). The main safety signals worth noting:

Acute-phase reactions. Fever, myalgia, and flu-like symptoms affected roughly one-third of patients after the first infusion. These were self-limiting (median duration 3 days) and declined sharply with subsequent doses. No patients withdrew from the trial solely because of these reactions.

Atrial fibrillation. Serious atrial fibrillation events were more common in the zoledronic acid group (1.3% vs. 0.5%, p = 0.003). This finding was unexpected and not explained by a clear biologic mechanism. Subsequent analyses and the companion HORIZON Recurrent Fracture Trial did not replicate the signal at the same magnitude, and the FDA concluded the association was uncertain but warranted monitoring and labeling disclosure.

Renal effects. Transient creatinine elevations occurred more frequently with zoledronic acid, but there was no increase in renal failure or dialysis. Current prescribing guidelines contraindicate use when creatinine clearance falls below 35 mL/min.

Osteonecrosis of the jaw (ONJ). One case was reported in the zoledronic acid group. ONJ has remained rare in osteoporosis-dose bisphosphonate therapy, with population-based estimates below 1 per 100,000 patient-years.

Limitations the Authors Acknowledged

The investigators were transparent about several constraints. The population was predominantly white postmenopausal women, limiting direct generalizability to men and non-white populations (the later HORIZON-RFT partially addressed this by enrolling hip fracture patients of both sexes). The atrial fibrillation signal was based on a secondary safety analysis and not adjudicated by a cardiac events committee.

Concomitant calcium and vitamin D supplementation in both arms means the observed fracture reduction reflects zoledronic acid plus baseline repletion, not the drug in isolation. Patients with severe renal impairment were excluded, so safety data in that subgroup remain limited.

The trial also did not compare zoledronic acid head-to-head with an oral bisphosphonate. Its design (drug vs. placebo) established efficacy in absolute terms but left the question of comparative superiority to indirect cross-trial analysis and later network meta-analyses, such as the Cochrane review of bisphosphonates for postmenopausal osteoporosis.

What It Means for Clinical Practice Today

The FDA approved zoledronic acid (branded as Reclast) for postmenopausal osteoporosis treatment in 2007 and for prevention in 2009. The Endocrine Society's 2019 clinical practice guideline lists IV zoledronic acid among first-line pharmacologic options for patients at high fracture risk.

Three practical implications have held up in the nearly two decades since HORIZON-PFT published:

Adherence advantage. Annual dosing eliminates the daily or weekly pill burden. For patients who cannot tolerate oral bisphosphonates or who have poor GI absorption, IV zoledronic acid provides a reliable alternative with verified drug delivery.

Duration of effect. Extension studies suggest that bone density gains persist for several years after discontinuation, giving zoledronic acid a longer "offset" effect than oral agents. This informs the concept of a bisphosphonate drug holiday, where treatment is paused after 3 to 6 years to reduce rare long-term risks like atypical femoral fractures.

Fracture reduction breadth. HORIZON-PFT remains one of the few osteoporosis trials to show statistically significant reduction in vertebral, hip, and non-vertebral fractures in a single study. Most oral bisphosphonate trials demonstrated vertebral fracture reduction convincingly but were individually underpowered for hip fracture endpoints.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809-1822. PubMed
2. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357(18):1799-1809. PubMed
3. Reclast (zoledronic acid) prescribing information. Novartis. Revised 2022. FDA Label
4. Eastell R, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1595-1622. PubMed
5. Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30(1):3-23. PubMed
6. Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008;(1):CD001155. PubMed